Misplaced Pages

Imeglimin

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
Imeglimin
Clinical data
Trade namesTwymeeg
ATC code
Legal status
Legal status
  • Rx-only in Japan
Identifiers
IUPAC name
  • (2S)-N,N,2-Trimethyl-1,2-dihydro-1,3,5-triazine-4,6-diamine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC6H13N5
Molar mass155.205 g·mol
3D model (JSmol)
SMILES
  • C1NC(=NC(=N1)N)N(C)C
InChI
  • InChI=1S/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m1/s1
  • Key:GFICWFZTBXUVIG-SCSAIBSYSA-N

Imeglimin (EMD- 387008,PXL- 008,RVT-1501, brand name Twymeeg) is an oral anti-diabetic medication. It was approved for use in Japan in June 2021.

It is an oxidative phosphorylation blocker that acts to inhibit hepatic gluconeogenesis, increase muscle glucose uptake, and restore normal insulin secretion. It is the first approved drug of this class of anti-diabetic medication.

References

  1. Vuylsteke V, Chastain LM, Maggu GA, Brown C (September 2015). "Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes". Drugs in R&D. 15 (3): 227–32. doi:10.1007/s40268-015-0099-3. PMC 4561051. PMID 26254210.
  2. Dubourg J, Fouqueray P, Thang C, Grouin JM, Ueki K (April 2021). "Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial". Diabetes Care. 44 (4): 952–959. doi:10.2337/dc20-0763. PMID 33574125.
  3. Poxel SA (June 23, 2021). "Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG® (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan" (Press release).
Oral diabetes medication, insulins and insulin analogs, and other drugs used in diabetes (A10)
Insulins / insulin analogs
fast-acting
short-acting
long-acting
ultra-long-acting
inhalable
  • Exubera
  • Afrezza
Non-insulins
Insulin sensitizers
Biguanides
TZDs/"glitazones" (PPAR)
Dual PPAR agonists
Amylin analogs and DACRAs
Secretagogues
KATP
Sulfonylureas
Meglitinides/"glinides"
GLP-1 receptor agonists
GLP1 poly-agonist peptides
DPP-4 inhibitors/"gliptins"
Other
Aldose reductase inhibitors
Alpha-glucosidase inhibitors
SGLT2 inhibitors/"gliflozins"
Other
Combinations
Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it.

Categories:
Imeglimin Add topic